Regeneron Pharmaceuticals, Inc. (REGN)

641.23
25.35 4.12
NASDAQ
Prev Close 615.88
Open 615.58
Day Low/High 612.20 / 644.34
52 Wk Low/High 271.37 / 655.93
Volume 860.12K
Exchange NASDAQ
Shares Outstanding 112.52B
Market Cap 69.86B
P/E Ratio 31.20
Div & Yield N.A. (N.A)
Regeneron Downtrend Ending But No Rush to Buy

Regeneron Downtrend Ending But No Rush to Buy

Stock still needs a period of base building to support advance.

Regeneron Downgraded at Raymond James

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

Thanks to the stock market correction many world-class stocks are back down to attractive levels.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet

Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet

Traders and investors should stand aside until the situation with this biotech name offers a better entry point.

Investors Shun Biotech Stocks

Investors Shun Biotech Stocks

The speed at which investors have bailed on this sector is alarming.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Regeneron Cut to Underweight at Barclays

Stalking Regeneron for Key Low and Reversal

Stalking Regeneron for Key Low and Reversal

Many swings on a particular chart tend to be similar to others.

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Shares have regained their 50-day moving average and look likely to push higher.

Regeneron Cut to Underperform at Baird

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Cramer: Rally Is Earning Some Trust

Cramer: Rally Is Earning Some Trust

The market rally broadened out nicely today.

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.

Regeneron Shows Green Shoots

Regeneron Shows Green Shoots

Clues in the chart point to higher prices to come.

Cramer: Retail Rally Shows the Perils of Being Too Negative

Cramer: Retail Rally Shows the Perils of Being Too Negative

There's a forest fire in the sector.

Regeneron Is Ready to Rally

Regeneron Is Ready to Rally

An upside breakout appears on the horizon.

Regeneron Could Generate More Upside

Regeneron Could Generate More Upside

Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.

Regeneron Is Ready to Reanimate: Watch for a Breakout

Regeneron Is Ready to Reanimate: Watch for a Breakout

This stock is testing resistance and could push back up to last year's highs.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.